Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotic Legislation Offers Big GAIN For Small Firm: Rib-X Extends Delafloxacin Exclusivity

This article was originally published in The Pink Sheet Daily

Executive Summary

Rib-X is among the first to take advantage of the Generating Antibiotic Incentives Now provisions of the FDA reauthorization legislation with five years’ extra exclusivity for its lead broad spectrum antibiotic candidate, a next-generation fluoroquinolone. Designation for the program came swiftly, company says.

You may also be interested in...



Antibiotic Exclusivity: Which Vision Will GAIN Upper Hand In FDA List-making?

Industry presenters tell FDA a broad list of potential diseases will attract more developer interest, but advocacy groups push for more targeted criteria during a public hearing on the new exclusivity incentive.

Without an IPO, Rib-X Raises $67.5 Million In Venture Funding

Rib-X will use the venture infusion to try to replicate Phase IIb data that indicated superiority to vancomycin for its broad-spectrum fluoroquinolone antibiotic.

GAIN Hearing Will Help FDA Set Pathogen List

The agency is seeking comments on the criteria prescribed in FDASIA and suggestions for other standards necessary to create a list of pathogens that qualified infectious disease products should target.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel